Freeline seeking ‘normal’ Factor IX activity via hemophilia gene therapy

Freeline has posted clinical potency data for its hemophilia B gene therapy that suggest its treatment could outperform its more advanced competitors.

Chris Hollowood, Freeline Therapeutics Ltd. executive chairman and Syncona Ltd. chief investment officer, told BioCentury that FLT180a led to potency levels in moderate to severe hemophilia B patients that have “never been seen in the field before” in the Phase I/II B-AMAZE trial (see Table: “Hemophilia B Gene Therapies”)...